vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Ranpak Holdings Corp. (PACK). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $93.7M, roughly 1.8× Ranpak Holdings Corp.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 2.3%). Over the past eight quarters, Ranpak Holdings Corp.'s revenue compounded faster (13.7% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Ranpak Holdings Corp. manufactures machines and paper products used in protective paper-based packing for shipping goods and merchandise for e-commerce and industry, along with automation solutions. The company is based in Concord, Ohio, and has production facilities and offices in Reno, Nevada; Kansas City, Missouri; the Netherlands; Czech Republic; Shanghai and Singapore. The paper packaging material can be used for multiple applications like wrapping, cushioning, void fill and cold chain p...
ESPR vs PACK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $93.7M |
| Net Profit | — | — |
| Gross Margin | — | 39.0% |
| Operating Margin | 50.6% | -1.0% |
| Net Margin | — | — |
| Revenue YoY | 143.7% | 2.3% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $93.7M | ||
| Q3 25 | $87.3M | $83.6M | ||
| Q2 25 | $82.4M | $77.8M | ||
| Q1 25 | $65.0M | $77.6M | ||
| Q4 24 | $69.1M | $91.6M | ||
| Q3 24 | $51.6M | $78.6M | ||
| Q2 24 | $73.8M | $72.8M | ||
| Q1 24 | $137.7M | $72.5M |
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $-10.4M | ||
| Q2 25 | $-12.7M | $-7.5M | ||
| Q1 25 | $-40.5M | $-10.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $-8.1M | ||
| Q2 24 | $-61.9M | $5.5M | ||
| Q1 24 | $61.0M | $-8.1M |
| Q4 25 | — | 39.0% | ||
| Q3 25 | — | 41.1% | ||
| Q2 25 | — | 37.1% | ||
| Q1 25 | — | 39.8% | ||
| Q4 24 | — | 45.2% | ||
| Q3 24 | — | 43.8% | ||
| Q2 24 | — | 43.5% | ||
| Q1 24 | — | 44.6% |
| Q4 25 | 50.6% | -1.0% | ||
| Q3 25 | -11.4% | -6.8% | ||
| Q2 25 | 8.6% | -12.5% | ||
| Q1 25 | -34.0% | -10.3% | ||
| Q4 24 | -6.4% | 1.5% | ||
| Q3 24 | -31.0% | -5.3% | ||
| Q2 24 | 3.5% | -7.1% | ||
| Q1 24 | 52.5% | -6.6% |
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | -12.4% | ||
| Q2 25 | -15.4% | -9.6% | ||
| Q1 25 | -62.2% | -14.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | -10.3% | ||
| Q2 24 | -83.9% | 7.6% | ||
| Q1 24 | 44.3% | -11.2% |
| Q4 25 | $0.32 | $-0.11 | ||
| Q3 25 | $-0.16 | $-0.12 | ||
| Q2 25 | $-0.06 | $-0.09 | ||
| Q1 25 | $-0.21 | $-0.13 | ||
| Q4 24 | $-0.14 | $-0.13 | ||
| Q3 24 | $-0.15 | $-0.10 | ||
| Q2 24 | $-0.33 | $0.07 | ||
| Q1 24 | $0.34 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $63.0M |
| Total DebtLower is stronger | — | $401.9M |
| Stockholders' EquityBook value | $-302.0M | $534.9M |
| Total Assets | $465.9M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.75× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $63.0M | ||
| Q3 25 | $92.4M | $49.9M | ||
| Q2 25 | $86.1M | $49.2M | ||
| Q1 25 | $114.6M | $65.5M | ||
| Q4 24 | $144.8M | $76.1M | ||
| Q3 24 | $144.7M | $69.5M | ||
| Q2 24 | $189.3M | $65.1M | ||
| Q1 24 | $226.6M | $55.1M |
| Q4 25 | — | $401.9M | ||
| Q3 25 | — | $403.1M | ||
| Q2 25 | — | $403.1M | ||
| Q1 25 | — | $405.2M | ||
| Q4 24 | — | $406.4M | ||
| Q3 24 | — | $403.2M | ||
| Q2 24 | — | $396.1M | ||
| Q1 24 | — | $396.7M |
| Q4 25 | $-302.0M | $534.9M | ||
| Q3 25 | $-451.4M | $537.8M | ||
| Q2 25 | $-433.5M | $539.0M | ||
| Q1 25 | $-426.2M | $544.1M | ||
| Q4 24 | $-388.7M | $548.1M | ||
| Q3 24 | $-370.2M | $564.3M | ||
| Q2 24 | $-344.2M | $566.2M | ||
| Q1 24 | $-294.3M | $560.0M |
| Q4 25 | $465.9M | $1.1B | ||
| Q3 25 | $364.0M | $1.1B | ||
| Q2 25 | $347.1M | $1.1B | ||
| Q1 25 | $324.0M | $1.1B | ||
| Q4 24 | $343.8M | $1.1B | ||
| Q3 24 | $314.1M | $1.1B | ||
| Q2 24 | $352.3M | $1.1B | ||
| Q1 24 | $373.1M | $1.1B |
| Q4 25 | — | 0.75× | ||
| Q3 25 | — | 0.75× | ||
| Q2 25 | — | 0.75× | ||
| Q1 25 | — | 0.74× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.71× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.71× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $19.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $19.5M | ||
| Q3 25 | $-4.3M | $8.5M | ||
| Q2 25 | $-31.4M | $-3.6M | ||
| Q1 25 | $-22.6M | $-1.3M | ||
| Q4 24 | $-35.0M | $6.5M | ||
| Q3 24 | $-35.3M | $10.1M | ||
| Q2 24 | $-7.2M | $19.6M | ||
| Q1 24 | $53.8M | $5.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.56× | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PACK
| Other | $47.9M | 51% |
| Europe And Asia Segment | $45.8M | 49% |
